Multigene Sequencing for Treatment Selection

Speaker: Christophe Le Tourneau

Prof. Christophe Le Tourneau explains that a term of precision medicine came along with a technology of multigene sequencing or assessment of multiple genes in a single assay. It can be applied now easily. Predictive value is about clinical utility of multigene sequencing, in other words does the multigene sequencing in cancer patients improves the outcome. Different molecular alterations that are assessed in multigene sequencing might have prognostic value. Testing recommendations depend on a kind of analysis and kind of tissue analysed.

Prof. Le Tourneau emphasises that we need a standardised way of assessing multigene sequencing, quality controls at every step, including sample collection, quality of tissue assessment, DNA extraction, and Bioinformatics.

Demonstration that multigene sequencing for treatment selection improves patient outcomes has not been shown so far. Multigene sequencing is performed in that regard either in the frame of clinical trial or molecular biology tumour boards in order to guide patient selection for clinical trials. He underlines on need for patients’ inclusion in the clinical trials.

You can find more information about this topic in the ESMO Factsheet on Multigene Sequencing for Treatment Selection.


  • What is a definition of multigene sequencing?
  • What is a predictive value of multigene sequencing?
  • What is a prognostic value of multigene sequencing?
  • What are currently testing recommendations for multigene sequencing for treatment selection?
  • How to ensure quality and timely testing results?
  • What are patient selection criteria?